A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males

Healthy Subjects Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02225288
• Other study ID #: E2022-J081-007
• Status: Completed
• Phase: Phase 1
• First received: August 22, 2014
• Last updated: March 31, 2015
• Start date: September 2014
• Est. completion date: February 2015

Study information

• Verified date: March 2015
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

This is a single-center, 4-group, open-label study in Japanese healthy elderly males. A total of 48 subjects will be randomized to one of four groups (A to D, 12 subjects/group) to administer one E2022 tape to designated sites.

Description:

This study consists of Screening, Treatment Period, and Follow-up. The Treatment Period is subdivided into three periods (Periods 1 to 3). Screening will start within 4 weeks before starting Treatment Period 1. In Treatment Periods 1 and 2, one E2022 tape will be applied to the designated site. The Treatment Period 2 application must have at least a 17-day interval from the end of Treatment Period 1 application. In Treatment Period 3, E2022 tape will be applied to back site (contralateral to the first applied site during Treatment Periods 1 and 2) after at least 17 days from the end of Treatment Period 2 (removing). A new E2022 tape will be applied to the same site after the specified intervals from the end of previous application (removing) in each group. Follow-up will start after at least a 17-day interval from the end of re-application in the Treatment Period 3 (removing).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: February 2015
• Est. primary completion date: December 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 65 Years and older

Eligibility

Inclusion Criteria

1. Male non-smokers (not smoking at least 4 weeks before Period 1) aged 65 years or older at informed consent

2. BMI at screening is 18.5 kg/m2 or above - below 28.0 kg/m2

3. Written informed consent

4. Given full explanation of this study and is willing to and able to comply with the protocol requirements

Exclusion Criteria

1. Have a current or past history of disorder requiring medical treatment within 8 weeks before the first application or infection within 4 weeks before the first application

2. Have a disorder within 4 weeks before the first application which affects the evaluation of study drug such as psychiatric, gastrointestinal, hepatic, renal, respiratory, endocrinological, hematological, neurological or cardiovascular system, or congenital metabolic abnormality

3. Have a history of gastrointestinal surgery (e.g., liver, kidney, digestive tract) which affects the pharmacokinetics of study drug

4. Have a history of treatment-requiring drug or food allergy or seasonal allergy at screening

5. Had caffeine-containing food or drink or alcohol within 72 hours before study drug application in Period 1

6. Had nutritional supplements, herbal preparations (including oriental medicines) or others (e.g., grapefruit-containing food or beverage) which may affect drug metabolizing enzymes and transporters, within 1 week before Period 1

7. Have used liquid products (including cosmetics) on study application sites (back, upper limb, chest), patch, tape or bandage, within 4 weeks before Period 1

8. Present or past clinical signs of skin hypersensitivity to topical product or atopic dermatitis

9. Excessively hairy or have shaved at application sites (back, upper limb, chest) within 4 weeks before Period 1

10. Eczema, dermatitis, abnormal pigmentation, injury, or scar at application sites which may affect the evaluation of skin symptoms

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• E2022
transdermal E2022 tape formulation (8.1 cm x 8.1 cm)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Eisai Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and frequency of adverse events		168 hours after the end of application	Yes
Secondary	Pharmacokinetics of E2022: Cmax	Maximal Drug Concentration (Cmax)	216 hours after the end of application	No
Secondary	Pharmacokinetics of E2022: AUC	Area Under the Plasma Concentration-Time Curve (AUC)	216 hours after the end of application	No
Secondary	Pharmacokinetics of E2022: Tmax	Time to Reach Maximum Observed Plasma Concentration (Tmax)	216 hours after the end of application	No
Secondary	Pharmacokinetics of E2022: t1/2	Plasma Decay Half-Life (t1/2)	216 hours after the end of application	No